SEC probes former Salix CEO, CFO over investor disclosure-source

WASHINGTON, Feb 9 (Reuters) - U.S. securities regulators are investigating whether former top executives at Salix Pharmaceuticals misled investors in connection with the company's 2014 disclosure that its drug inventory levels were much higher than previously reported, according to a person familiar with the probe.